Microba Life Sciences Ltd

Microba Life Sciences has a liquidity position that is characterized by a current ratio of 1.87, indicating that the company has sufficient current assets to cover its current liabilities. However, the company's operating cash flow is negative at -12,012,510 AUD, and its free cash flow is also negative at -13,407,660 AUD, suggesting that the company is not generating positive cash from operations. The company's cash and equivalents amount to 2,715,000 AUD, which is less than its long-term debt of 3,229,650 AUD, indicating a net cash negative position. In terms of profitability, Microba Life Sciences is currently unprofitable, with a net income of -14,939,470 AUD and an operating income of -17,648,000 AUD. The company's return on equity is -45.98%, and its return on assets is -31.49%, both of which are significantly below the industry median for healthcare companies. The gross profit margin is 47.47%, which is relatively high, but the company's operating margin is -112.64%, indicating that the company is not able to convert its gross profit into operating profit. Microba Life Sciences does not provide segment-specific revenue data, but its geographic exposure is primarily in Australia, with global testing services offered to researchers, clinicians, and consumers. The company's revenue concentration is not disclosed, but its operations are primarily in the healthcare sector, which is subject to regulatory and reimbursement risks. The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. The company's operating cash flow and free cash flow are both negative, which may limit its ability to invest in growth opportunities. The company's capital expenditure is -2,899,370 AUD, indicating that it is not investing in new assets. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag is that the company's net cash is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The company's dilution potential is low, and no significant adjustments have been applied to its valuation metrics. Recent events include analyst estimates that suggest a mean price target of 0.20 AUD and a median price target of 0.20 AUD, with a mean recommendation of 1.50 (1=strong buy, 5=strong sell). The company has one strong-buy and one buy recommendation, with no hold recommendations. These analyst estimates suggest a generally positive outlook, but the company's financial performance will need to improve to meet these targets.